Showing results (141-150 of 197) with videos related to
Sort By:
Pageof 20
The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.The New England Journal of Medicine|July 9, 2015
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque PsoriasisKenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, et al.Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.Journal of Drugs in Dermatology : JDD|February 6, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc AnalysesKenneth B Gordon, Joseph F Merola, Peter Foley, et al.Journal of the American Academy of Dermatology|March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialCraig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.The Journal of Investigative Dermatology|June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 StudyKenneth B Gordon, April W Armstrong, Peter Foley, et al.The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.Journal of the American Academy of Dermatology|November 11, 2023
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)Richard B Warren, Lars E French, Andrew Blauvelt, et al.Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.Pageof 20